Stock XOMAO XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Delayed Nasdaq
Other stock markets
 21:30:00 06/06/2024 BST 		5-day change 1st Jan Change
25.1 USD +0.44% Intraday chart for XOMA Corporation -0.90% -0.08%
05-09 Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M MT
05-09 XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Advance Friday Afternoon
XOMA Agrees to Acquire Kinnate Biopharma
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment
Xoma Names Owen Hughes as Chief Executive Officer
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
XOMA Authorizes $50 Million Share Buyback Program
XOMA Authorizes $50 Million Share Buyback Program
XOMA Corporation announces an Equity Buyback for $50 million worth of its shares.
XOMA Corporation authorizes a Buyback Plan.
Sector Update: Health Care Stocks Gain in Afternoon Trading
Xoma Gets Up To $140 Million Royalty-Backed Loan From Blue Owl Capital; Xoma Shares Rise
Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital
XOMA Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. XOMAO Stock
  5. News XOMA Corporation
  6. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW